CD8A and neoplasm: SR1078 is an agonist of RORα/γ, which inhibited NF-κB function and enhanced CD8+ T-cell responses in the Jurkat T cell leukemia cell line. Agonists of RORγ including LYC-54143 and LYC-53772 blocked differentiation of Th17 cells as well as immunosuppression and also elevated cytokine levels, thus showed anti-tumor properties by both reducing immune suppression and enhancing immune activation